Complementing the randomized controlled trial evidence base: Evolution not revolution

Annals of the American Thoracic Society

Volumn 11, Issue SUPPL. 2, 2014, Pages

  Price, David ^a,b   Bateman, Eric D ^b,c   Chisholm, Alison ^b   Papadopoulos, Nikolaos G ^b,d   Bosnic Anticevich, Sinthia ^b,e   Pizzichini, Emilio ^b,f   Hillyer, Elizabeth V ^b   Buist, A Sonia ^b,g  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b Respiratory Effectiveness Group   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF ATHENS   (Greece)

^e UNIVERSITY OF SYDNEY   (Australia)

^f FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Complementary; Integrated evidence base; Observational study; Pragmatic trial; Randomized controlled trial

Indexed keywords

CLINICAL PRACTICE; CONCEPTUAL FRAMEWORK; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DOCTOR PATIENT RELATION; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL ETHICS; OBSERVATIONAL STUDY; PATIENT ATTITUDE; PATIENT MONITORING; PATIENT PREFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EVIDENCE-BASED MEDICINE; HUMANS; OBSERVATIONAL STUDY AS TOPIC; PRAGMATIC CLINICAL TRIALS AS TOPIC; PULMONARY MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84898748102     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201308-276RM     Document Type: Conference Paper

References (39)

1. Conway PH, Clancy C. Comparative-effectiveness research - implications of the Federal Coordinating Council 's report. N Engl J Med 2009;361:328-330.
2. GRADE Working Group. Grading of recommendations assessment, development and evaluation (GRADE) [Internet] [accessed 2013 Aug 15]. Available from: http://www.gradeworkinggroup.org/
3. Herland K, Akselsen JP, Skjønsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir Med 2005;99:11-19. (Pubitemid 40017378)
4. Travers J, Marsh S, Caldwell B, Williams M, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. External validity of randomized controlled trials in COPD. Respir Med 2007;101:1313-1320. (Pubitemid 46667661)
5. Konstantinou GN. Pragmatic trials: how to adjust for the 'Hawthorneeffect'? Thorax 2012;67:562. Author reply p. 562.
6. Lenney W, Perry S, Price D. Clinical trials and tribulations: the MASCOT study. Thorax 2011;66:457-458.
7. Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, Juniper EF, Ayres JG, Kemp L, Blyth A, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011;364:1695-1707.
8. Global Initiative for Asthma. GINA report, global strategy for asthma management and prevention, updated 2012 [Internet] [accessed 2013 Aug 15]. Available from: www.ginasthma.org
9. Price D, Chisholm A, Hillyer EV, Burden A, Von Ziegenweidt J, Svedsater H, Dale P. Effect of inhaled corticosteroid therapy stepdown and dosing regimen on measures of asthma control. J Aller Ther 2013;4:1-8.
10. Clinical Practice Research Datalink [Internet] [accessed 2013 Aug 15]. Available from: http://www.cprd.com/home/.
11. Optimum Patient Care Research Database (OPCRD) [Internet] [accessed 2013 Aug 15]. Available from: http://www. optimumpatientcare.org/Html-Docs/OPCRD.html
12. Smith JR, Noble MJ, Musgrave S, Murdoch J, Price GM, Barton GR, Windley J, Holland R, Harrison BD, Howe A, et al. The At-Risk Registers In Severe Asthma (ARRISA) study: a cluster-randomised controlled trial examining effectiveness and costs in primary care. Thorax 2012;67:1052-1060.
13. Price D, Hillyer EV, van der Molen T. Efficacy versus effectiveness trials: informing guidelines for asthma management. Curr Opin Allergy Clin Immunol 2013;13:50-57.
14. Thomas M, Price D. Impact of comorbidities on asthma. Expert Rev Clin Immunol 2008;4:731-742.
15. Clatworthy J, Price D, Ryan D, Haughney J, Horne R. The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. Prim Care Respir J 2009;18:300-305.
16. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002;57:226-230. (Pubitemid 34214408)
17. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003;168:1308 -1311.
18. Gallefoss F, Bakke PS. Does smoking affect the outcome of patient education and self-management in asthmatics? Patient Educ Couns 2003;49:91-97. (Pubitemid 36071314)
19. Althuis MD, Sexton M, Prybylski D. Cigarette smoking and asthma symptom severity among adult asthmatics. J Asthma 1999;36: 257-264. (Pubitemid 29267546)
20. Hakala K, Stenius-Aarniala B, Sovijärvi A. Effects of weight loss on peak flow variability, airways obstruction, and lung volumes in obese patients with asthma. Chest 2000;118:1315-1321.
21. Saint-Pierre P, Bourdin A, Chanez P, Daures JP, Godard P. Are overweight asthmatics more difficult to control? Allergy 2006;61: 79-84. (Pubitemid 43381195)
22. Lavoie KL, Bacon SL, Labrecque M, Cartier A, Ditto B. Higher BMI is associated with worse asthma control and quality of life but not asthma severity. Respir Med 2006;100:648 -657.
23. Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003;16:249-254. (Pubitemid 37169635)
24. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 2002;19: 246-251. (Pubitemid 34162824)
25. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004;363:731-733. (Pubitemid 38296564)
26. Dahlén SE, Dahlén B, Drazen JM. Asthma treatment guidelines meet the real world. N Engl J Med 2011;364:1769-1770.
27. Papi A, Haughney J, Virchow JC, Roche N, Palkonen S, Price D. Inhaler devices for asthma: a call for action in a neglected fi eld. Eur Respir J 2011;37:982 -985.
28. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, Smaldone GC, Guyatt G; American College of Chest Physicians; American College of Asthma, Allergy, and Immunology. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005;127:335-371. (Pubitemid 41724594)
29. Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, Douglas G, Muers M, Smith D, White J. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001;5: 1-149.
30. British Thoracic Society (BTS), Scottish Intercollegiate Guidelines Network (SIGN). British guideline on the management of asthma [Internet]. May 2008 [accessed 2013 Aug 15]. Available from: http://www.sign.ac.uk/guidelines/ fulltext/101/index.html
31. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma [Internet]. 2007 [accessed 2013 Aug 15]. Available from: http://www.nhlbi.nih.gov/guidelines/asthma/ asthgdln.pdf
32. Price D, Haughney J, Sims E, Ali M, von Ziegenweidt J, Hillyer EV, Lee AJ, Chisholm A, Barnes N. Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD. J Asthma Allergy 2011;4:37-47.
33. Price D, Roche N, Christian Virchow J, Burden A, Ali M, Chisholm A, Lee AJ, Hillyer EV, von Ziegenweidt J. Device type and real-world effectiveness of asthma combination therapy: an observational study. Respir Med 2011;105:1457 -1466.
34. Roche N, Reddel HK, Agusti A, Batemand ED, Krishnan JA, Martin RJ, Papi A, Postma D, Thomas M, Brusselle G, et al. Integrating real-life studies in the global therapeutic research framework. Lancet Respir Med 2013;1:30-32.
35. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Gibson P, Ohta K, O'Byrne P, Pedersen SE, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143-178.
36. Tomlinson JE, McMahon AD, Chaudhuri R, Thompson JM, Wood SF, Thomson NC. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax 2005;60: 282-287. (Pubitemid 40522363)
37. Price D, Popov TA, Bjermer L, Lu S, Petrovic R, Vandormael K, Mehta A, Strus JD, Polos PG, Philip G. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol 2013;131: 763-771.
38. Chavannes N, Ställberg B, Lisspers K, Roman M, Moran A, Langhammer A, Crockett A, Cave A, Williams S, Jones R, et al. UNLOCK: Uncovering and Noting Long-Term Outcomes in COPD to enhance Knowledge. Prim Care Respir J 2010;19:408.
39. Roche N, Reddel H, Martin R, Brusselle G, Papi A, Thomas M, Postma D, Thomas V, Rand C, Chisholm A, et al.; Respiratory Effectiveness Group. Quality standards for real-world research: focus on observational database studies of comparative effectiveness. Ann Am Thorac Soc 2014;11:S99-S104.